Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer

Abstract Background Triple-negative breast cancer (TNBC) is currently the most aggressive subtype of breast cancer, characterized by high heterogeneity and strong invasiveness, and currently lacks effective therapies. PRMT5, a type II protein arginine methyltransferase, is upregulated in numerous ca...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Yaxun Guo, Yuzhan Li, Zhongmei Zhou, Lei Hou, Wenjing Liu, Wenlong Ren, Dazhao Mi, Jian Sun, Xueqin Dai, Yingying Wu, Zhuo Cheng, Tingyue Wu, Qianmei Luo, Cong Tian, Fubing Li, Zhigang Yu, Yihua Chen, Ceshi Chen
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2024-11-01
Sarja:	Journal of Experimental & Clinical Cancer Research
Aiheet:	PROTAC PRMT5 KLF5 TNBC
Linkit:	https://doi.org/10.1186/s13046-024-03237-y
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!